Refine
Document Type
- Doctoral Thesis (2)
Language
- English (2) (remove)
Has Fulltext
- yes (2)
Is part of the Bibliography
- no (2)
Keywords
- Kaltes Plasma (2)
- CAP (1)
- Melanom (1)
- Mitochondrium (1)
- Plasmamedizin (1)
There has been a substantial evolution of anti-cancer therapies in the last decade, leading
to improved prognosis and disease-free survival of patients with melanoma. Due to the
number of patients that still develop resistance or to the high systemic toxicity and side
effects, new treatment options are still needed. Regardless of the type of therapeutic
interventions (except surgery), the reactive oxygen species (ROS) are a by-product or
contribute to the action mechanism of many successful therapies. In this context, medical
cold atmospheric plasma (CAP) arises as a promising tool, and studies are important to
prove the effectiveness of this new device.
Since combination therapies are the current standard way to treat melanoma, we explored
candidates to be combined with cold atmospheric plasma, with potential to become a
therapeutic option in the combination. Here, we tested the radiotherapy and clinically safe
mitochondrial inhibitor drugs. In the end of the study, both, ionizing radiation and four
mitochondrial-targeted-drugs showed to be promising candidates for the combination with
CAP. These combinations induced increased cytotoxicity and modulated the immune
system improving the anti-tumor immune response. Mitochondrial damage seems to be
the first stage to induce cellular deficiency and culminate in apoptotic cell death.
Furthermore the release of GM-CSF contribute to a pro inflammatory state and immune
system activation.
This dissertation showed that CAP serves as an excellent tool to boost melanoma cell
death and induce anti-tumor response. In addition, in our proposed therapeutic
combination, the intensity of plasma treatment could be decreased possibly resulting in
less systemic toxicity. Our results serves as model to be studied in other tumor entities.
Due to a variety of plasma sources in terms of type of discharge, energy yield, working gas or geometric factors, it is recommended to standardize the study protocol by choosing a plasma source and easy access to rugged tumor surfaces as demonstrated by the CAP-plasma-jet. The intention of the trial shall be to optimize the plasma jet for tumor site capability and operating room implementation.
It makes sense to start clinical trials in plasma medicine with the treatment of head and neck squamous cell carcinoma patients of infected wounds and ulcerations.
CAP is able to reduce contamination of cancer ulcerations and the typical fetid odor that often accompanies head and neck cancer patients. The intention of the trial shall be to evaluate the efficiency of decontamination in head and neck cancer ulcerations in terms of pathogenic species, amount of reduction and reliability.
Standardize study protocol:
Phase I, clinical explorative single-arm, randomized, open, multicenter
Primary objective
Reduction of microbial burden of cancer ulcerations by application of CAP
Secondary objective:
Reduction of tumor following local CAP application
Inclusion:
20 Patients suffering from locally advanced oral cavity carcinoma with open tumor surfaces, treated with palliative intention and no more curative treatment options
Exclusion:
No wish for treatment, no compliance and understanding the protocol of the clinical study
Efficacy:
reduction of microbial burden; Documentation of visible changes by photography; Pathohistological and biochemical examination of specimen, taken from the tumor area and control areas
Procedure:
Plasma is applied for 1 minute per cm², spot area of 3 mm diameter distance between nozzle and tumor surface of 14 mm. 3 times/week with a break of 1 week followed by a repeated cycle for another week.
Conclusion:
The most important intention of the trial from the clinician’s point of view shall be to make CAP-treatment an effective and well-accepted addition to standard cancer therapy based upon EBM at least in palliative medicine.